Article
Patterson Belknap Webb & Tyler LLP | USA | 18 Feb 2021
The Federal Circuit considered its 35 U.S.C. § 112 enablement case law and found that “the enablement inquiry for claims that include functional…
Article
Patterson Belknap Webb & Tyler LLP | USA | 18 Feb 2021
On February 9, 2021, District Judge Lorna Schofield (S.D.N.Y.) denied defendant Google LLC’s motion for summary judgment on the defense of equitable…
Article
Patterson Belknap Webb & Tyler LLP | USA | 17 Feb 2021
Last summer, we wrote about two principles of New York law that could provide a path to insurance coverage for businesses hit hard by the economic…
Article
Patterson Belknap Webb & Tyler LLP | USA | 17 Feb 2021
A CLE was recently presented by the Columbian Lawyers Association of the First Department on February 3, 2021 to offer guidance on the latest rule…
Audio
Patterson Belknap Webb & Tyler LLP | USA | 16 Feb 2021
Congress draws on Article IV and the Corfield opinion to craft a new privileges and immunities clause, but the Supreme Court quickly narrows its…
Article
Patterson Belknap Webb & Tyler LLP | USA | 12 Feb 2021
Federal law expressly authorizes manufacturers of dietary supplements to make “structure/function” claims—that is, claims about the effect of…
Article
Patterson Belknap Webb & Tyler LLP | USA | 11 Feb 2021
Staples’ parent company recently announced plans for an attempt to buy all outstanding stock of Office Depot’s parent company (ODP) for $2.1 billion…
Article
Patterson Belknap Webb & Tyler LLP | USA | 10 Feb 2021
In McCloud v. United States, the Second Circuit (Walker, Raggi, Nardini) rejected the petitioner's contention that a development in Circuit law…
Article
Patterson Belknap Webb & Tyler LLP | USA | 9 Feb 2021
In Farro v. Schochet, the Second Department recently held that §1002 of the NY LLC Law restricted a dissenting member’s remedy to an appraisal for…
Article
Patterson Belknap Webb & Tyler LLP | USA | 9 Feb 2021
On February 5, 2021, the FDA approved Juno Therapeutics, Inc.’s Breyanzi® (lisocabtagene maraleucel) for “treatment of adult patients with relapsed…